Bristol Myers Squibb (BMY) Receivables - Other (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Receivables - Other for 18 consecutive years, with $108.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Receivables - Other fell 93.66% year-over-year to $108.0 million in Q2 2026; TTM through Jun 2026 was $108.0 million, a 93.66% decrease from a year earlier, with the FY2025 full-year figure at $1.8 billion, up 4.96% from the prior year.
• Receivables - Other was $108.0 million for Q2 2026 at Bristol Myers Squibb, down from $1.4 billion in the prior quarter.
• Over five years, Receivables - Other peaked at $2.2 billion in Q1 2023 and troughed at $108.0 million in Q2 2026.
• A 5-year average of $1.3 billion and a median of $1.6 billion in 2022 frame the typical range for Receivables - Other.
• Across the five-year window, Receivables - Other surged 62.36% in 2023 and tumbled 93.66% in 2026, its largest moves.
• Over 5 years, Receivables - Other stood at $504.0 million in 2022, then slipped by 17.46% to $416.0 million in 2023, then declined by 7.45% to $385.0 million in 2024, then plunged by 50.13% to $192.0 million in 2025, then sank by 43.75% to $108.0 million in 2026.
• The last three Receivables - Other figures came in at $108.0 million (Q2 2026), $1.4 billion (Q1 2026), and $192.0 million (Q4 2025), per Business Quant data.